Researchers developed a rapid, noninvasive tool called CaST that tracks neurons and biomolecules activated by psychedelic drugs. This new method allows researchers to observe the cellular processes responsible for the neuroplastic effects of psychedelics, offering insights into treatments for brain disorders like depression and PTSD.

A new study reveals that psilocybin, the active compound in magic mushrooms, temporarily disrupts brain networks involved in introspective thinking, like daydreaming and memory. These changes persist for weeks, potentially making the brain more flexible and improving mental health. The findings could pave the way for psilocybin-based therapies for depression and PTSD. The research underscores the importance of using these drugs under medical supervision.